No new data or financial impact in this abstract-only announcement. Monitor EAACI presentations on June 14 for any substantive efficacy or safety readouts from the Phase 1 CDX-622 data or barzolvolimab long-term results; near-term price reaction likely muted unless unexpected positive/negative signals emerge.
Price Chart
Executive Summary
Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical profile in CSU and cold urticaria, plus a late-breaking poster on first-in-human Phase 1 results for CDX-622, a bispecific targeting TSLP and mast cells. This is a routine scientific conference update with no new efficacy or safety data disclosed, providing no material stock-moving catalyst.
Key Facts
- Three presentations to be given at EAACI Annual Congress, June 12-15, 2026, in Istanbul, Türkiye
- Two flash talks on barzolvolimab: one on long-term off-treatment angioedema improvement in CSU, another on psychometric validation of WI-NRS in cold urticaria
- Late-breaking poster on Phase 1 first-in-human results of CDX-622 (bispecific targeting TSLP and mast cells via SCF) in healthy volunteers
- Barzolvolimab is in Phase 3 studies for CSU and ColdU/SD, and Phase 2 studies for prurigo nodularis and atopic dermatitis
Financial Impact
No financial data disclosed; pipeline milestone update with no dollar amounts or revenue impact
Risk Factors
- Barzolvolimab Phase 3 results may fail to replicate Phase 2 efficacy or safety
- CDX-622 is early-stage (Phase 1); no guarantee of clinical benefit or regulatory path
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310079 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▼ −19.96% | ▼ −20.71% | $31.22 (+2.82%) |
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▲ +19.96% | ▲ +20.71% | $31.22 (−2.82%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $31.22 (+4.19%) |
Jun 10, 2026 16w ago | Press Release | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $31.22 (+4.19%) |
May 7, 2026 21w ago | 8-K | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.22 (−8.11%) |
May 7, 2026 21w ago | Press Release | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.22 (−8.11%) |
Apr 6, 2026 25w ago | Press Release | $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $31.22 (−0.49%) |
Apr 2, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.22 (+0.50%) |
Apr 1, 2026 26w ago | 424B5 | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.22 (+0.50%) |
Apr 1, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.22 (+0.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access